A phase 2 trial of Indivior Pharmaceuticals’ opioid use disorder (OUD) candidate has missed its primary endpoint. Indivior ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral ...

Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...

Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of ...

BeOne Medicines is paying $20 million upfront to reserve the right to buy a preclinical trispecific antibody from China’s ...

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with ...

Labcorp is raising its 2026 guidance, buoyed by demand across its diagnostics and central laboratory businesses. | Labcorp is ...

Transplant-focused precision medicine company CareDx is making a move into the oncology space, scooping up ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...

AstraZeneca will resume a 300 million pound ($404 million) investment program in the U.K. seven months after freezing the ...